Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease

Completed · Phase 1 · Has a placebo group

Conditions studied: Alzheimer's Disease

In brief

The primary objective of the study is to evaluate the safety and tolerability of a range of BIIB037 doses administered as single intravenous (IV) infusions in participants with mild to moderate Alzheimer's Disease (AD). Secondary objectives of this study in this study population are to assess the pharmacokinetics(PK) and to evaluate the immunogenicity of BIIB037 after single-dose administration.

Key facts

Study ID

NCT01397539

Run by

Biogen

People needed

53

Starts

2011-06-01

Expected to finish

2013-08-01

Last updated by the study team

2015-03-23

Who can join

Age: 55 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Brain Matters Research — Delray Beach, Florida, United States
• Compass Research, LLC — Orlando, Florida, United States
• Insight Clinical Trials, LLC — Beachwood, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.